Skip to Main Content

There are a few angles through which to view Tuesday’s acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals, but let’s start positively.

A buyout deal is happening in biotech, which is struggling mightily right now. Granted, this takeout is not a blockbuster — Regeneron is paying $250 million in cash to acquire Checkmate — but any deal at this point should help boost sentiment in a sector that has been abandoned by investors in 2022.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Create a display name to comment

This name will appear with your comment